DPHL: A DIA Pan-human Protein Mass Spectrometry Library for Robust Biomarker Discovery
Tiansheng Zhu,Yi Zhu,Yue Xuan,Huanhuan Gao,Xue Cai,Sander R Piersma,Thang V Pham,Tim Schelfhorst,Richard R G D Haas,Irene V Bijnsdorp,Rui Sun,Liang Yue,Guan Ruan,Qiushi Zhang,Mo Hu,Yue Zhou,Winan J Van Houdt,Tessa Y S Le Large,Jacqueline Cloos,Anna Wojtuszkiewicz,Danijela Koppers-Lalic,Franziska Böttger,Chantal Scheepbouwer,Ruud H Brakenhoff,Geert J L H van Leenders,Jan N M Ijzermans,John W M Martens,Renske D M Steenbergen,Nicole C Grieken,Sathiyamoorthy Selvarajan,Sangeeta Mantoo,Sze S Lee,Serene J Y Yeow,Syed M F Alkaff,Nan Xiang,Yaoting Sun,Xiao Yi,Shaozheng Dai,Wei Liu,Tian Lu,Zhicheng Wu,Xiao Liang,Man Wang,Yingkuan Shao,Xi Zheng,Kailun Xu,Qin Yang,Yifan Meng,Cong Lu,Jiang Zhu,Jin'e Zheng,Bo Wang,Sai Lou,Yibei Dai,Chao Xu,Chenhuan Yu,Huazhong Ying,Tony K Lim,Jianmin Wu,Xiaofei Gao,Zhongzhi Luan,Xiaodong Teng,Peng Wu,Shi'ang Huang,Zhihua Tao,Narayanan G Iyer,Shuigeng Zhou,Wenguang Shao,Henry Lam,Ding Ma,Jiafu Ji,Oi L Kon,Shu Zheng,Ruedi Aebersold,Connie R Jimenez,Tiannan Guo
DOI: https://doi.org/10.1016/j.gpb.2019.11.008
Abstract:To address the increasing need for detecting and validating protein biomarkers in clinical specimens, mass spectrometry (MS)-based targeted proteomic techniques, including the selected reaction monitoring (SRM), parallel reaction monitoring (PRM), and massively parallel data-independent acquisition (DIA), have been developed. For optimal performance, they require the fragment ion spectra of targeted peptides as prior knowledge. In this report, we describe a MS pipeline and spectral resource to support targeted proteomics studies for human tissue samples. To build the spectral resource, we integrated common open-source MS computational tools to assemble a freely accessible computational workflow based on Docker. We then applied the workflow to generate DPHL, a comprehensive DIA pan-human library, from 1096 data-dependent acquisition (DDA) MS raw files for 16 types of cancer samples. This extensive spectral resource was then applied to a proteomic study of 17 prostate cancer (PCa) patients. Thereafter, PRM validation was applied to a larger study of 57 PCa patients and the differential expression of three proteins in prostate tumor was validated. As a second application, the DPHL spectral resource was applied to a study consisting of plasma samples from 19 diffuse large B cell lymphoma (DLBCL) patients and 18 healthy control subjects. Differentially expressed proteins between DLBCL patients and healthy control subjects were detected by DIA-MS and confirmed by PRM. These data demonstrate that the DPHL supports DIA and PRM MS pipelines for robust protein biomarker discovery. DPHL is freely accessible at https://www.iprox.org/page/project.html?id=IPX0001400000.